Register Login

All Posts

Anti-Xa DOAC Assay Variability

Click here to read an open-access article describing the variability in assay methodology when monitoring apixaban and rivaroxaban: Baker RM, Selby R, Moffat KA, St John M, Spyropoulos AC, Schulman S, Douketis J. Investigating interassay variability between direct oral anticoagulant calibrated anti-factor Xa assays: a substudy of the perioperative anticoagulation use for surgery evaluation (PAUSE) […]
read more

Autoimmune Acquired Coagulation Factor Deficiencies

Click here for the open-access review of Ichinose A, Osaki T, Souri M. Diagnosis and treatment of autoimmune acquired coagulation factor deficiencies: an evidence-based review of Japanese practice. Semin Thromb Hemost. 2025;51:491-505. doi: 10.1055/s-0044-1787188. Epub 2024 Jun 12. PMID: 38866039. Abstract Among the acquired coagulation factor deficiencies, autoimmune coagulation factor deficiencies (AiCFD) are rare and […]
read more

Postpartum DIC

Check with your medical library for this review, dated 7-18-25. Wolfovitz A, Brenner B, Solt I. Postpartum disseminated intravascular coagulation: A comprehensive review of pathophysiology, diagnosis, management, and prevention. Semin Thromb Hemost. doi: 10.1055/a-2645-2845. Epub ahead of print. PMID: 40680793. Abstract Disseminated intravascular coagulation (DIC) in the postpartum period is a rare but potentially life-threatening […]
read more

Poster: Monitoring FVIII in Hemophilia Patients Treated with Bypassing Therapeutics

To review the PBI poster presented at the 2025 ISTH meeting, click Effect of Mim8 and Emicizumab on Factor VIII Recovery by a Novel, Bovine Chromogenic FVIII Assay. Tara Quinton, Meghan Bruhm, Karen M. Black, Ali Sadeghi-Khomami. Precision BioLogic Inc., Dartmouth, Nova Scotia, Canada. The poster illustrates the validity of bovine reagent-based chromogenic substrate FVIII […]
read more

July 2025 Quick Question: Hemophilia Therapeutics

At the June 21–25 ISTH meeting in Washington, DC, we heard several quality presentations describing the new hemophilia treatment materials, including updated EHL concentrates plus the bypassing, rebalancing, and gene transfer therapies. In follow-up, our July 2025 Quick Question asks you to select the choice that represents the recently approved rebalancing therapies. Please make your […]
read more